TRV GP II’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

TRV GP II’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.34M	Sell	572,829 -775,000	-57%	-$2.74M	100%	1
2022 Q2	$4.08M	Hold	1,347,829	–	–	88.46%	1
2022 Q1	$9.15M	Sell	1,347,829 -1,350,000	-50%	-$9.62M	93.42%	1
2021 Q4	$22.5M	Hold	2,697,829	–	–	93.16%	1
2021 Q3	$20M	Sell	2,697,829 -1,750,000	-39%	-$10.8M	88.84%	1
2021 Q2	$30.2M	Sell	4,447,829 -2,052,520	-32%	-$17.1M	89.29%	1
2021 Q1	$66.8M	Sell	6,500,349 -2,700,000	-29%	-$29.6M	42.19%	2
2020 Q4	$64.4M	Sell	9,200,349 -1,030,000	-10%	-$8.02M	44.86%	2
2020 Q3	$83.5M	Hold	10,230,349	–	–	54.19%	1
2020 Q2	$70.6M	Hold	10,230,349	–	–	52.18%	1
2020 Q1	$48.6M	Hold	10,230,349	–	–	52.19%	1
2019 Q4	$89.3M	Hold	10,230,349	–	–	92.14%	1
2019 Q3	$34.1M	Hold	10,230,349	–	–	75.6%	1
2019 Q2	$50.6M	Hold	10,230,349	–	–	81.68%	1
2019 Q1	$63.4M	Hold	10,230,349	–	–	41.35%	2
2018 Q4	$34.5M	Hold	10,230,349	–	–	34.25%	2
2018 Q3	$66.5M	Hold	10,230,349	–	–	39.03%	2
2018 Q2	$78.4M	Hold	10,230,349	–	–	44.43%	1
2018 Q1	$229M	Hold	10,230,349	–	–	42.85%	1
2017 Q4	$130M	Buy	+10,230,349	New	+$150M	23.49%	2

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

TRV GP II's JNCE Position: Q3 2022 in Review

TRV GP II reduced its Jounce Therapeutics, Inc. Common Stock (JNCE) stake by 57% in Q3 2022, selling an estimated $2.74M and leaving 572,829 shares worth $1.34M. The position accounts for 100% of the portfolio, ranked #1.

TRV GP II first reported a position in JNCE in Q4 2017 and has held it in 20 quarters since. The position peaked at $229M in Q1 2018. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

TRV GP II held 572,829 shares of Jounce Therapeutics, Inc. Common Stock worth $1.34M as of Q3 2022.
TRV GP II sold 775,000 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.74M.
Jounce Therapeutics, Inc. Common Stock made up 100% of TRV GP II's portfolio in Q3 2022, its #1 holding.
TRV GP II first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and has held it in 20 quarters since.
TRV GP II's Jounce Therapeutics, Inc. Common Stock position peaked at $229M in Q1 2018.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on TRV GP II's 13F filing for Q3 2022, filed 3 Nov 2022.